NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00.Invest ...

Ameritas Advisory Services LLC lowered its position in shares of Novartis AG (NYSE:NVS – Free Report) by 2.7% during the 4th ...

Koshinski Asset Management Inc. boosted its holdings in Novartis AG (NYSE:NVS – Free Report) by 6.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission ...

In a report released today, Peter Welford from Jefferies maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target ...

Welcome to the Novartis presentation at the 43rd JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to introduce Vas Narasimhan ...

Plaque Psoriasis BURLINGAME, CA, UNITED STATES, January 27, 2025 /EINPresswire / -- The worldwide Plaque Psoriasis <a target=_blank href=h ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure ...

Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan ...

Europe Pharmaceutical Drugs Market Projected To Witness Substantial Growth, 2025-2032: Astrazeneca., Baxter, Novartis AG Europe pharmaceutical drugs market is estimated to be valued at US$ 180.2 Bn in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...